A Multicentric, Prospective, Comparative, Randomized Phase-IV Study For Evaluation Of Efficacy And Safety Of Efonidipine 40mg Tablet In Comparison to Cilnidipine 10 Mg Tablet In The Management Of Hypertension

Zuventus Healthcare Limited0 个研究点目标入组 1,200 人开始时间: 待定最近更新: 2024年5月27日

试验速览

暂无简介。

•1. Patients aged 18 to 65 years
•2. Patients with Stage 1 hypertension (SBP/DBP: 140-159/90-99 mmHg) or stage II(SBP/DBP: =160/100 mmHg) hypertension as per Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VII)
•2.1. Subgroup of patients with stage I hypertension: Patients diagnosed with Stage I hypertension (JNC VII)
•2.2. Subgroup of patients with renal impairment: Stage I or stage II hypertensive patients (JNC VII) diagnosed with renal impairment who do not need dialysis or replacement therapy
•2.3. Subgroup of patients with Diabetes: Stage I or stage II hypertensive (JNC VII) patients with diabetes
•3. Patients willing to sign informed consent

•1. Patient with cerebrovascular disease in the previous 3 months.
•2. Patients with congestive heart failure, chronic arrhythmia, sick sinus syndrome or sinus bradycardia ( < 50 beats/min)
•3. Patients with second- or third-degree atrioventricular block
•4. Patients with documented hypersensitivity to dihydropyridine calcium channel blockers or Efonidipine HCl
•5. Women who are pregnant or breast feeding

发起方